RaQualia Pharma Inc

RaQualia Pharma Inc maintains a capital structure with a debt-to-equity ratio of 0.68, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 3.66, suggesting strong short-term liquidity. However, the company's operating cash flow is negative at -410,189,000 JPY, and free cash flow is also negative at -53,494,000 JPY, indicating that the company is not generating sufficient cash from operations to fund its activities. The company's price-to-book ratio of 2.33 suggests that the market is valuing the company at a premium to its book value.

In terms of profitability, RaQualia Pharma Inc is underperforming relative to industry norms. The company's return on equity (ROE) is -1.3%, and its return on assets (ROA) is -0.73%, both of which are negative and significantly below the typical performance metrics for the pharmaceutical industry. The company's net income is negative at -78,106,000 JPY, indicating a loss for the period. The gross profit margin is 90.6%, which is high, but the operating margin is only 2.7%, reflecting high operating expenses relative to revenue.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification could expose the company to higher risk if demand in its primary market or product line declines. The company's revenue for the period is 648,581,000 JPY, with a gross profit of 588,049,000 JPY. The company's operating income is 17,449,000 JPY, which is significantly lower than its gross profit, indicating high operating expenses.

The company's growth trajectory is uncertain, as the provided data does not include forward-looking revenue projections or historical growth rates. The company's capital expenditures are -20,531,000 JPY, indicating a reduction in capital spending. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital or reduce debt in the near term.

Recent events and disclosures for RaQualia Pharma Inc are not detailed in the provided data. The company's analyst estimates indicate that the last actual EPS was 11.53 JPY and the last actual revenue was 3,979,960,000 JPY. These figures suggest that the company's performance may have declined in the most recent reporting period.

The company's valuation metrics, including an enterprise value to EBITDA ratio of 850.99 and an enterprise value to revenue ratio of 22.89, suggest that the company is highly valued relative to its earnings and revenue. These high multiples may reflect market expectations of future growth or the company's position in a high-growth segment of the pharmaceutical industry.

Revenue surged 28.1% year-over-year to JPY 3.98 billion in fiscal 2026, demonstrating strong top-line growth momentum.

Free cash flow improved dramatically by 428.1% to JPY 686.6 million, signaling a robust return to positive cash generation.

Operating income jumped 315.3% to JPY 509.9 million, indicating significant operational leverage and improved core profitability.

Cash conversion ratio of 5.25 ranks best-in-class among 857 pharmaceutical peers, highlighting superior cash management efficiency.

Net income turned positive at JPY 273.1 million in fiscal 2026, reversing previous losses and restoring bottom-line profitability.

Debt-to-equity ratio of 0.68 sits in the bottom quartile of peers, indicating significantly higher financial leverage and risk.

The company faces high credit risk, suggesting potential difficulties in meeting financial obligations or securing favorable financing terms.

Medium liquidity risk flags potential constraints in meeting short-term obligations, requiring careful monitoring of cash flow stability.

Revenue ¥1.67B, +126,1% YoY; Operating income +486,5% YoY.

• ▍Revenue ¥1.67B, +126,1% YoY
• ▍Operating income +486,5% YoY
• ▍Net income +642,8% YoY
• ▍Free cash flow +3 004,9% YoY
• ▍Net margin 50.5%

Revenue ¥775.1M, −19,1% YoY; Operating income −184,6% YoY.

• ▍Revenue ¥775.1M, −19,1% YoY
• ▍Operating income −184,6% YoY
• ▍Net income −1 236,2% YoY
• ▍Free cash flow −478,7% YoY
• ▍Net margin -27.6%

Revenue ¥570.6M, −25,2% YoY; Operating income −21,7% YoY.

• ▍Revenue ¥570.6M, −25,2% YoY
• ▍Operating income −21,7% YoY
• ▍Net income −42,2% YoY
• ▍Free cash flow −79,4% YoY
• ▍Net margin -61.3%

Revenue ¥965.4M, +48,9% YoY; Operating income +549,4% YoY.

• ▍Revenue ¥965.4M, +48,9% YoY
• ▍Operating income +549,4% YoY
• ▍Net income +93,3% YoY
• ▍Free cash flow +289,2% YoY
• ▍Net margin -0.5%

Revenue ¥738.1M; Operating income -¥213.2M.

• ▍Revenue ¥738.1M
• ▍Operating income -¥213.2M
• ▍Net margin -21.0%

Revenue ¥958.4M; Operating income ¥182.9M.

• ▍Revenue ¥958.4M
• ▍Operating income ¥182.9M
• ▍Net margin -1.7%

Revenue ¥762.5M; Operating income -¥224.1M.

• ▍Revenue ¥762.5M
• ▍Operating income -¥224.1M
• ▍Net margin -32.2%

Revenue ¥648.6M; Operating income ¥17.4M.

• ▍Revenue ¥648.6M
• ▍Operating income ¥17.4M
• ▍Net margin -12.0%

Revenue ¥3.98B, +28,1% YoY; Operating income +315,2% YoY.

• ▍Revenue ¥3.98B, +28,1% YoY
• ▍Operating income +315,2% YoY
• ▍Net income +155,2% YoY
• ▍Free cash flow +428,1% YoY
• ▍Net margin 6.9%

Revenue ¥3.11B, +63,5% YoY; Operating income +34,0% YoY.

• ▍Revenue ¥3.11B, +63,5% YoY
• ▍Operating income +34,0% YoY
• ▍Net income −53,0% YoY
• ▍Free cash flow +40,8% YoY
• ▍Net margin -15.9%

Revenue ¥1.90B, −34,9% YoY; Operating income −144,8% YoY.

• ▍Revenue ¥1.90B, −34,9% YoY
• ▍Operating income −144,8% YoY
• ▍Net income −144,7% YoY
• ▍Free cash flow −142,1% YoY
• ▍Net margin -17.0%

Revenue ¥2.92B, +5,1% YoY; Operating income +16,4% YoY.

• ▍Revenue ¥2.92B, +5,1% YoY
• ▍Operating income +16,4% YoY
• ▍Net income −4,3% YoY
• ▍Free cash flow +6,0% YoY
• ▍Net margin 24.8%